Skip to main content
Erschienen in: Pediatric Cardiology 2/2016

01.02.2016 | Original Article

High Frequency of Detection by PCR of Viral Nucleic Acid in The Blood of Infants Presenting with Clinical Myocarditis

verfasst von: Kathleen E. Simpson, Gregory A. Storch, Caroline K. Lee, Kent E. Ward, Saar Danon, Catherine M. Simon, Jeffrey W. Delaney, Alan Tong, Charles E. Canter

Erschienen in: Pediatric Cardiology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Specific viruses are associated with pediatric myocarditis, but the prevalence of viral DNAemia detected by blood polymerase chain reaction (PCR) is unknown. We evaluated the prevalence of known cardiotropic viruses (enterovirus, adenovirus, human herpesvirus 6, and parvovirus B19) in children with clinical myocarditis (n = 21). Results were compared to pediatric controls with similar viral PCR testing. The majority of positive PCR (89 %) was noted in children ≤12 months of age at diagnosis compared to older children. Infant myocarditis patients (8/10) had increased the prevalence of PCR positivity compared to infant pediatric controls (4/114) (p < 0.0001). Other than age, patient characteristics at diagnosis were similar between PCR-positive and PCR-negative patients. Both PCR-negative myocarditis infants had clinical recovery at follow-up. Of the PCR-positive myocarditis infants, 4 had clinical recovery, 2 developed chronic cardiomyopathy, 1 underwent heart transplant, and 1 died. Infants with clinical myocarditis have a high rate of blood viral positivity, which is higher compared to older children with myocarditis and healthy infant controls. Age-related differences in PCR positivity may be due to differences in host and/or virus characteristics. Our findings suggest that viral blood PCR may be a useful diagnostic tool and identify patients who would potentially benefit from virus-specific therapy.
Literatur
1.
Zurück zum Zitat Andrews RE et al (2008) New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland. Circulation 117(1):79–84CrossRefPubMed Andrews RE et al (2008) New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland. Circulation 117(1):79–84CrossRefPubMed
2.
Zurück zum Zitat Bauer S et al (2002) Severe Coxsackie virus B infection in preterm newborns treated with pleconaril. Eur J Pediatr 161(9):491–493CrossRefPubMed Bauer S et al (2002) Severe Coxsackie virus B infection in preterm newborns treated with pleconaril. Eur J Pediatr 161(9):491–493CrossRefPubMed
5.
Zurück zum Zitat Daliento L et al (2003) Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 22(2):214–217CrossRefPubMed Daliento L et al (2003) Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 22(2):214–217CrossRefPubMed
6.
Zurück zum Zitat Daubeney PE et al (2006) Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 114(24):2671–2678CrossRefPubMed Daubeney PE et al (2006) Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 114(24):2671–2678CrossRefPubMed
7.
Zurück zum Zitat Durani Y et al (2009) Pediatric myocarditis: presenting clinical characteristics. Am J Emerg Med 27(8):942–947CrossRefPubMed Durani Y et al (2009) Pediatric myocarditis: presenting clinical characteristics. Am J Emerg Med 27(8):942–947CrossRefPubMed
8.
Zurück zum Zitat Florescu DF, Keck MA (2014) Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther 12(10):1171–1178CrossRefPubMed Florescu DF, Keck MA (2014) Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther 12(10):1171–1178CrossRefPubMed
9.
Zurück zum Zitat Florescu DF et al (2012) Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 18(5):731–738PubMedCentralCrossRefPubMed Florescu DF et al (2012) Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 18(5):731–738PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Heim A et al (1996) Recombinant interferons beta and gamma have a higher antiviral activity than interferon-alpha in coxsackievirus B3-infected carrier state cultures of human myocardial fibroblasts. J Interferon Cytokine Res 16(4):283–287CrossRefPubMed Heim A et al (1996) Recombinant interferons beta and gamma have a higher antiviral activity than interferon-alpha in coxsackievirus B3-infected carrier state cultures of human myocardial fibroblasts. J Interferon Cytokine Res 16(4):283–287CrossRefPubMed
11.
Zurück zum Zitat Kuhl U et al (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107(22):2793–2798CrossRefPubMed Kuhl U et al (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107(22):2793–2798CrossRefPubMed
12.
Zurück zum Zitat Lim BK et al (2015) Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model. Virus Res 199:1–8CrossRefPubMed Lim BK et al (2015) Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model. Virus Res 199:1–8CrossRefPubMed
13.
Zurück zum Zitat Lipshultz SE et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348(17):1647–1655CrossRefPubMed Lipshultz SE et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348(17):1647–1655CrossRefPubMed
14.
Zurück zum Zitat Pevear DC et al (1999) Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43(9):2109–2115PubMedCentralPubMed Pevear DC et al (1999) Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43(9):2109–2115PubMedCentralPubMed
15.
Zurück zum Zitat Rotbart HA, Webster AD, Pleconaril G (2001) Treatment registry, treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32(2):228–235CrossRefPubMed Rotbart HA, Webster AD, Pleconaril G (2001) Treatment registry, treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32(2):228–235CrossRefPubMed
16.
Zurück zum Zitat Towbin JA et al (2006) Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296(15):1867–1876CrossRefPubMed Towbin JA et al (2006) Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296(15):1867–1876CrossRefPubMed
17.
Zurück zum Zitat Yun SH et al (2012) Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J Infect Dis 205(3):491–497CrossRefPubMed Yun SH et al (2012) Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J Infect Dis 205(3):491–497CrossRefPubMed
Metadaten
Titel
High Frequency of Detection by PCR of Viral Nucleic Acid in The Blood of Infants Presenting with Clinical Myocarditis
verfasst von
Kathleen E. Simpson
Gregory A. Storch
Caroline K. Lee
Kent E. Ward
Saar Danon
Catherine M. Simon
Jeffrey W. Delaney
Alan Tong
Charles E. Canter
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 2/2016
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-015-1290-6

Weitere Artikel der Ausgabe 2/2016

Pediatric Cardiology 2/2016 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.